aspartic acid has been researched along with Myocardial Infarction in 69 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The protective effect of aspartate and glutamate in isoproterenol induced myocardial infarction (MI) was investigated in experimental animals." | 3.77 | Aspartate and glutamate prevents isoproterenol-induced cardiac toxicity by alleviating oxidative stress in rats. ( Babu, PV; Shyamaladevi, CS; Sivakumar, R, 2011) |
| "Therefore, early detection of heart attack and investigation of potential new biomarkers are of great importance." | 1.72 | Effects of perilipin-5 on lipid metabolism and high-sensitivity cardiac troponin I. ( Ethem, İ; Hacıoğlu, C, 2022) |
| "Reperfusion arrhythmias were reduced by LL-TBOA (P = 0." | 1.40 | A novel glutamate transporter blocker, LL-TBOA, attenuates ischaemic injury in the isolated, perfused rat heart despite low transporter levels. ( Danbolt, NC; Dehnes, Y; Holmseth, S; Martinov, V; Shimamoto, K; Valen, G, 2014) |
| "The metabolic alterations of type 2 diabetes are associated with protection against IR injury at onset but detrimental effects in late diabetes mellitus consistent with progressive dysfunction of glucose oxidation." | 1.39 | Protection against myocardial ischemia-reperfusion injury at onset of type 2 diabetes in Zucker diabetic fatty rats is associated with altered glucose oxidation. ( Birkler, RI; Bøtker, HE; Dalgas, C; Johannsen, M; Løfgren, B; Povlsen, JA; Støttrup, NB, 2013) |
| "Haemochromatosis is a common genetic disorder, inherited as an autosomal recessive trait that results in a progressive accumulation of iron in most tissues of the body." | 1.31 | Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. ( Amarenco, P; Arveiler, D; Cambien, F; Elbaz, A; Evans, A; Gariepy, J; Grandchamp, B; Hetet, G; Kee, F; Morrison, C; Nicaud, V; Simon, A, 2001) |
| "Myocardial infarction was produced in rats by left coronary artery ligation." | 1.30 | Aspartate improves recovery of the recently infarcted rat heart after cardioplegic arrest. ( Fisher, JL; Korchazhkina, OV; Pisarenko, OI; Richards, SM; Rosenfeldt, FL; Tong, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (52.17) | 18.7374 |
| 1990's | 5 (7.25) | 18.2507 |
| 2000's | 15 (21.74) | 29.6817 |
| 2010's | 10 (14.49) | 24.3611 |
| 2020's | 3 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, M | 2 |
| Chen, J | 1 |
| Wang, Y | 1 |
| Kang, G | 1 |
| Zhang, Y | 1 |
| Han, X | 1 |
| Ethem, İ | 1 |
| Hacıoğlu, C | 1 |
| Wang, AP | 1 |
| Suryavanshi, T | 1 |
| Marcucci, M | 1 |
| Fong, C | 1 |
| Whitton, AC | 1 |
| Reddy, KKV | 1 |
| Marian, AJ | 1 |
| Povlsen, JA | 2 |
| Løfgren, B | 2 |
| Dalgas, C | 1 |
| Birkler, RI | 1 |
| Johannsen, M | 2 |
| Støttrup, NB | 3 |
| Bøtker, HE | 3 |
| Martinov, V | 1 |
| Dehnes, Y | 1 |
| Holmseth, S | 1 |
| Shimamoto, K | 1 |
| Danbolt, NC | 1 |
| Valen, G | 1 |
| Chouchani, ET | 1 |
| Pell, VR | 1 |
| Gaude, E | 1 |
| Aksentijević, D | 1 |
| Sundier, SY | 1 |
| Robb, EL | 1 |
| Logan, A | 1 |
| Nadtochiy, SM | 1 |
| Ord, ENJ | 1 |
| Smith, AC | 1 |
| Eyassu, F | 1 |
| Shirley, R | 1 |
| Hu, CH | 1 |
| Dare, AJ | 1 |
| James, AM | 1 |
| Rogatti, S | 1 |
| Hartley, RC | 1 |
| Eaton, S | 1 |
| Costa, ASH | 1 |
| Brookes, PS | 1 |
| Davidson, SM | 1 |
| Duchen, MR | 1 |
| Saeb-Parsy, K | 1 |
| Shattock, MJ | 1 |
| Robinson, AJ | 1 |
| Work, LM | 1 |
| Frezza, C | 1 |
| Krieg, T | 1 |
| Murphy, MP | 1 |
| Moon, J | 1 |
| Kang, W | 1 |
| Oh, PC | 1 |
| Seo, SY | 1 |
| Lee, K | 1 |
| Han, SH | 1 |
| Ahn, T | 1 |
| Shin, E | 1 |
| Jespersen, NR | 1 |
| Yokota, T | 1 |
| Bergdahl, A | 1 |
| Paelestik, KB | 1 |
| Dela, F | 1 |
| Sivakumar, R | 2 |
| Anandh Babu, PV | 1 |
| Shyamaladevi, CS | 2 |
| Odeberg, J | 1 |
| Larsson, CA | 1 |
| Råstam, L | 1 |
| Lindblad, U | 1 |
| Schwarz, ER | 1 |
| Tussing, T | 1 |
| Skobel, E | 1 |
| Klosterhalfen, B | 1 |
| Domanski, D | 1 |
| Fuess, JE | 1 |
| Theodoraki, EV | 1 |
| Nikopensius, T | 1 |
| Suhorutsenko, J | 1 |
| Papamikos, V | 1 |
| Kolovou, GD | 1 |
| Peppes, V | 1 |
| Panagiotakos, D | 1 |
| Limberi, S | 1 |
| Zakopoulos, N | 1 |
| Metspalu, A | 1 |
| Dedoussis, GV | 1 |
| Babu, PV | 1 |
| Isordia-Salas, I | 1 |
| Leaños-Miranda, A | 1 |
| Borrayo-Sánchez, G | 1 |
| Birkler, RD | 1 |
| Nielsen, JM | 1 |
| Wang, L | 1 |
| Caldarone, CA | 1 |
| Kristiansen, SB | 1 |
| Contractor, H | 1 |
| Nielsen, TT | 1 |
| González-Loyola, A | 1 |
| Barba, I | 1 |
| Bäckström, T | 1 |
| Goiny, M | 1 |
| Lockowandt, U | 1 |
| Liska, J | 1 |
| Franco-Cereceda, A | 1 |
| Pisarenko, OI | 4 |
| Shul'zhenko, VS | 1 |
| Studneva, IM | 3 |
| Lepilin, MG | 1 |
| WEBER, B | 1 |
| LABORIT, H | 3 |
| JOUANY, JM | 1 |
| NIAUSSAT, P | 1 |
| BARON, C | 1 |
| GROSSI, F | 1 |
| Zee, RY | 1 |
| Hegener, HH | 1 |
| Gould, J | 1 |
| Ridker, PM | 1 |
| Huang, F | 1 |
| Shan, J | 1 |
| Reiken, S | 1 |
| Wehrens, XH | 1 |
| Marks, AR | 1 |
| Iakoubova, OA | 1 |
| Tong, CH | 1 |
| Chokkalingam, AP | 1 |
| Rowland, CM | 1 |
| Kirchgessner, TG | 1 |
| Louie, JZ | 1 |
| Ploughman, LM | 1 |
| Sabatine, MS | 1 |
| Campos, H | 1 |
| Catanese, JJ | 1 |
| Leong, DU | 1 |
| Young, BA | 1 |
| Lew, D | 1 |
| Tsuchihashi, Z | 1 |
| Luke, MM | 1 |
| Packard, CJ | 1 |
| Zerba, KE | 1 |
| Shaw, PM | 1 |
| Shepherd, J | 1 |
| Devlin, JJ | 1 |
| Sacks, FM | 1 |
| Serebryakova, LI | 1 |
| Tskitishvili, OV | 1 |
| Morray, B | 1 |
| Goldenberg, I | 1 |
| Moss, AJ | 1 |
| Zareba, W | 1 |
| Ryan, D | 1 |
| McNitt, S | 1 |
| Eberly, SW | 1 |
| Glazko, G | 1 |
| Mathew, J | 1 |
| Li, J | 1 |
| Zhang, Q | 1 |
| Egger, M | 1 |
| Capritti, AG | 1 |
| Jiang, XR | 1 |
| Chen, WP | 1 |
| Shi, HL | 1 |
| Zhou, LF | 1 |
| Laborit, G | 1 |
| Stasiński, T | 1 |
| Walczak-Mińko, R | 1 |
| Kostka-Wach, M | 1 |
| Biryńczyk, J | 1 |
| Kawczyńska, D | 1 |
| Wróz, M | 1 |
| Al-Mudhaffar, SA | 1 |
| Shakib, MI | 1 |
| Al-Hassan, SS | 1 |
| Schlack, W | 1 |
| Bier, F | 1 |
| Schäfer, M | 1 |
| Uebing, A | 1 |
| Schäfer, S | 1 |
| Borchard, U | 1 |
| Thämer, V | 1 |
| Rosenfeldt, FL | 1 |
| Korchazhkina, OV | 1 |
| Richards, SM | 1 |
| Fisher, JL | 1 |
| Tong, S | 1 |
| Cai, H | 1 |
| Wang, X | 1 |
| Colagiuri, S | 1 |
| Wilcken, DE | 1 |
| Nishiyama, Y | 1 |
| Nejima, J | 1 |
| Watanabe, A | 1 |
| Kotani, E | 1 |
| Sakai, N | 1 |
| Hatamochi, A | 1 |
| Shinkai, H | 1 |
| Kiuchi, K | 1 |
| Tamura, K | 1 |
| Shimada, T | 1 |
| Takano, T | 1 |
| Katayama, Y | 1 |
| Hetet, G | 1 |
| Elbaz, A | 1 |
| Gariepy, J | 1 |
| Nicaud, V | 1 |
| Arveiler, D | 1 |
| Morrison, C | 1 |
| Kee, F | 1 |
| Evans, A | 1 |
| Simon, A | 1 |
| Amarenco, P | 1 |
| Cambien, F | 1 |
| Grandchamp, B | 1 |
| Amin, WM | 1 |
| Rose, R | 1 |
| Leshchinskiĭ, LA | 2 |
| Trusov, VV | 1 |
| Shinkareva, IA | 2 |
| Jansen, W | 1 |
| Jacobi, H | 1 |
| Slezák, J | 2 |
| Tribulová, N | 2 |
| Lazarenko, VG | 1 |
| Engelman, RM | 1 |
| Rousou, JA | 1 |
| Flack, JE | 1 |
| Iyengar, J | 1 |
| Kimura, Y | 1 |
| Das, DK | 1 |
| Teboul, J | 1 |
| Doustaly, C | 1 |
| Monnot, F | 1 |
| Sanchez, B | 1 |
| Popoff, G | 1 |
| Kreitmann, P | 1 |
| Beyersdorf, F | 1 |
| Acar, C | 1 |
| Buckberg, GD | 1 |
| Partington, MT | 1 |
| Okamoto, F | 1 |
| Allen, BS | 1 |
| Young, HH | 1 |
| Bugyi, HI | 1 |
| Singh, J | 1 |
| Garg, KN | 1 |
| Garg, D | 1 |
| Chugh, K | 1 |
| Lal, H | 1 |
| Pisarenko, O | 1 |
| Studneva, I | 1 |
| Khlopkov, V | 1 |
| Solomatina, E | 1 |
| Ruuge, E | 1 |
| Kühn, P | 1 |
| Koller, H | 1 |
| Kohn, P | 1 |
| Holzhey, P | 1 |
| Gavrilescu, S | 1 |
| Luca, C | 1 |
| Fiat, F | 1 |
| Grujic, M | 1 |
| Perinovic, M | 1 |
| London, JW | 1 |
| Yarrish, R | 1 |
| Dzubow, LD | 1 |
| Garfinkel, D | 1 |
| Geizerová, H | 1 |
| Widimský, J | 1 |
| Iakushev, VS | 2 |
| Lifshits, RI | 2 |
| Slobodin, VB | 2 |
| Briukhin, GV | 1 |
| Vasků, J | 1 |
| Bednarík, B | 1 |
| Urbánek, E | 1 |
| Efimenko, GP | 1 |
| Szulc, EJ | 1 |
| Kizer, DE | 1 |
| Howell, BA | 1 |
| Máté, K | 1 |
| Stepantschitz, G | 1 |
| Fröhlich, E | 1 |
| Martinesi, L | 1 |
| Belli, C | 1 |
| Reichertz, PL | 1 |
| Noell, G | 1 |
| Hemmati, A | 1 |
| Kabelitz, HJ | 1 |
| Samofalova, MS | 1 |
| Dockweiler, J | 1 |
| Nikolits, I | 1 |
| Szám, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cardiac Mitochondrial Function After Heart Transplantation[NCT04105803] | 64 participants (Anticipated) | Observational | 2019-04-25 | Enrolling by invitation | |||
| Cardiac Mitochondrial Function in Explanted Human Hearts[NCT04500938] | 24 participants (Anticipated) | Observational | 2020-08-30 | Not yet recruiting | |||
| Phase III Study of Metabolic Intervention With Glutamate in Coronary Surgery II[NCT02592824] | Phase 3 | 321 participants (Actual) | Interventional | 2015-11-15 | Completed | ||
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Postoperative mortality was defined as mortality within 30 days of surgery. (NCT02592824)
Timeframe: up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 1 |
| Intravenous Saline Infusion | 6 |
suspected unexpected serious adverse reaction (NCT02592824)
Timeframe: within 24 hours from infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 0 |
"Postoperative stroke was defined as neurological or cognitive deficit with a cerebral injury verified on (Computed Tomography) CT-scan. All suspected cases of stroke underwent CT-scan.~Stroke within 24 h of surgery was defined as a stroke that occurred within 24 h of surgery or signs of a stroke, when first assessable in deeply sedated patients on a ventilator." (NCT02592824)
Timeframe: within 24 hours from surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 4 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~In the first GLUTAMICS trial a good agreement between hemodynamic criteria for postoperative heart failure and postoperative NT-proBNP was found." (NCT02592824)
Timeframe: from the day before surgery to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 5390 |
| Intravenous Saline Infusion | 6452 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~Previous observations suggest a blunted effect of glutamate in diabetic hearts." (NCT02592824)
Timeframe: from preoperative level to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4503 |
| Intravenous Saline Infusion | 6825 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: first postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4438 |
| Intravenous Saline Infusion | 4420 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 8055 |
| Intravenous Saline Infusion | 8804 |
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
2 reviews available for aspartic acid and Myocardial Infarction
| Article | Year |
|---|---|
Intravenous magnesium for acute myocardial infarction.
Topics: Aspartic Acid; Humans; Injections, Intravenous; Magnesium Chloride; Magnesium Compounds; Magnesium S | 2007 |
[New experimental data on the physiopathology of myocardial necrosis and its treatment].
Topics: Animals; Aspartic Acid; Glucose; Hypertension; Insulin; Lysosomes; Myocardial Infarction; Potassium; | 1983 |
2 trials available for aspartic acid and Myocardial Infarction
| Article | Year |
|---|---|
[Secondary prevention in patients after myocardial infarction by means of Tromcardin forte (author's transl)].
Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Drug Evaluation; Humans; Middle Aged; Myocardi | 1974 |
[Clinical studies on the therapeutic effect of potassium-magnesium aspartate in coronary disease].
Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Coronary Disease; Female; Humans; Magnesium; M | 1968 |
65 other studies available for aspartic acid and Myocardial Infarction
| Article | Year |
|---|---|
Network Pharmacology-Based Combined with Experimental Validation Study to Explore the Underlying Mechanism of
Topics: Agrimonia; Animals; Antioxidants; Aspartic Acid; bcl-2-Associated X Protein; Caspase 3; Creatine Kin | 2022 |
Effects of perilipin-5 on lipid metabolism and high-sensitivity cardiac troponin I.
Topics: Adult; Aspartic Acid; Biomarkers; Calcium; Creatine; Creatine Kinase; Glutathione; Humans; L-Lactate | 2022 |
Radiation Necrosis Following Stereotactic Radiosurgery for Trigeminal Neuralgia.
Topics: Aged, 80 and over; Aspartic Acid; Brain Diseases; Brain Neoplasms; Choline; Creatine; Diagnostic Err | 2020 |
Non-syndromic cardiac progeria in a patient with the rare pathogenic p.Asp300Asn variant in the LMNA gene.
Topics: Adult; Amino Acid Sequence; Asparagine; Aspartic Acid; Base Sequence; Coronary Artery Disease; Echoc | 2017 |
Protection against myocardial ischemia-reperfusion injury at onset of type 2 diabetes in Zucker diabetic fatty rats is associated with altered glucose oxidation.
Topics: Animals; Aspartic Acid; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Heart Function Tests; Hem | 2013 |
A novel glutamate transporter blocker, LL-TBOA, attenuates ischaemic injury in the isolated, perfused rat heart despite low transporter levels.
Topics: Amino Acid Transport System X-AG; Animals; Arrhythmias, Cardiac; Aspartic Acid; Excitatory Amino Aci | 2014 |
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS.
Topics: Adenosine Monophosphate; Animals; Aspartic Acid; Citric Acid Cycle; Disease Models, Animal; Electron | 2014 |
Serum transaminase determined in the emergency room predicts outcomes in patients with acute ST-segment elevation myocardial infarction who undergo primary percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Aspartic Acid; Biomarkers; Emergency Service, Hospita | 2014 |
Pre-ischaemic mitochondrial substrate constraint by inhibition of malate-aspartate shuttle preserves mitochondrial function after ischaemia-reperfusion.
Topics: Aminooxyacetic Acid; Animals; Aspartic Acid; Cardiotonic Agents; Cell Respiration; Citric Acid Cycle | 2017 |
Pre-ischaemic mitochondrial substrate constraint by inhibition of malate-aspartate shuttle preserves mitochondrial function after ischaemia-reperfusion.
Topics: Aminooxyacetic Acid; Animals; Aspartic Acid; Cardiotonic Agents; Cell Respiration; Citric Acid Cycle | 2017 |
Pre-ischaemic mitochondrial substrate constraint by inhibition of malate-aspartate shuttle preserves mitochondrial function after ischaemia-reperfusion.
Topics: Aminooxyacetic Acid; Animals; Aspartic Acid; Cardiotonic Agents; Cell Respiration; Citric Acid Cycle | 2017 |
Pre-ischaemic mitochondrial substrate constraint by inhibition of malate-aspartate shuttle preserves mitochondrial function after ischaemia-reperfusion.
Topics: Aminooxyacetic Acid; Animals; Aspartic Acid; Cardiotonic Agents; Cell Respiration; Citric Acid Cycle | 2017 |
Protective effect of aspartate and glutamate on cardiac mitochondrial function during myocardial infarction in experimental rats.
Topics: Animals; Aspartic Acid; Disease Models, Animal; Enzyme Activation; Glutamic Acid; Glutathione; Gluta | 2008 |
The Asp298 allele of endothelial nitric oxide synthase is a risk factor for myocardial infarction among patients with type 2 diabetes mellitus.
Topics: Alleles; Aspartic Acid; Data Collection; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Age | 2008 |
Application of zinc-bis-(DL-hydrogensaspartate) does not reduce apoptotic cell death in myocardial infarction in the rat heart.
Topics: Animals; Apoptosis; Aspartic Acid; Cardiovascular Agents; Disease Models, Animal; Echocardiography; | 2009 |
ROS1 Asp2213Asn polymorphism is not associated with coronary artery disease in a Greek case-control study.
Topics: Aged; Asparagine; Aspartic Acid; Case-Control Studies; Female; Greece; Humans; Male; Middle Aged; My | 2009 |
Aspartate and glutamate prevents isoproterenol-induced cardiac toxicity by alleviating oxidative stress in rats.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Aspartic Acid; Cardiotonic Agents; Disease Models, An | 2011 |
The Glu298ASP polymorphism of the endothelial nitric oxide synthase gene is associated with premature ST elevation myocardial infarction in Mexican population.
Topics: Adult; Alleles; Amino Acid Substitution; Aspartic Acid; Case-Control Studies; Electrocardiography; E | 2010 |
Inhibition of the malate-aspartate shuttle by pre-ischaemic aminooxyacetate loading of the heart induces cardioprotection.
Topics: Aminooxyacetic Acid; Animals; Aspartic Acid; Cardiotonic Agents; Cell Respiration; Energy Metabolism | 2010 |
Mitochondrial metabolism revisited: a route to cardioprotection.
Topics: Aminooxyacetic Acid; Animals; Aspartic Acid; Cardiotonic Agents; Cell Respiration; Energy Metabolism | 2010 |
[Caution in therapy of ventricular extrasystole. Staying safe with electrolytes].
Topics: Anti-Arrhythmia Agents; Aspartic Acid; Cardiac Complexes, Premature; Cause of Death; Drug Combinatio | 2002 |
Cardiac outflow of amino acids and purines during myocardial ischemia and reperfusion.
Topics: Amino Acids; Animals; Aspartic Acid; Female; Guanosine; Hemodynamics; Hypoxanthine; Inosine; Male; M | 2003 |
[Effects of metabolic substrates and mannitol on efficiency of cardioplegic protection in isolated rat heart].
Topics: Animals; Aspartic Acid; Cardioplegic Solutions; Diastole; Diuretics, Osmotic; Heart; Male; Mannitol; | 2003 |
[Changes of the electrocardiographic signs of experimental myocardial infarct in the rabbit caused by injection of salts of aspartic acid].
Topics: Animals; Aspartic Acid; Electrocardiography; Injections; Myocardial Infarction; Physical Examination | 1958 |
[Possibilities of the aspartates in various diseases of the myocardium].
Topics: Aspartic Acid; Myocardial Infarction; Myocardium | 1963 |
Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis.
Topics: Amino Acid Substitution; Aspartic Acid; Case-Control Studies; Genetic Predisposition to Disease; Gly | 2005 |
Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of heart failure by calstabin2 in mice.
Topics: Animals; Aspartic Acid; Catalysis; Disease Models, Animal; Electrophysiology; Gene Expression Regula | 2006 |
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
Topics: Alleles; Anticholesteremic Agents; Antigens, CD; Asparagine; Aspartic Acid; Coronary Disease; Geneti | 2006 |
Metabolic correction reduces the area of acute ischemic myocardial infarction in rats.
Topics: Animals; Aspartic Acid; Glucose; Male; Mannitol; Myocardial Infarction; Myocardial Ischemia; Myocard | 2006 |
Polymorphisms in the paraoxonase and endothelial nitric oxide synthase genes and the risk of early-onset myocardial infarction.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Arginine; Aryldialkylphosphatase; Aspartic Acid; Cohor | 2007 |
[Therapy of some diseases of the myocardium with potassium aspartate].
Topics: Adult; Aged; Arrhythmias, Cardiac; Aspartic Acid; Female; Heart Block; Humans; Male; Middle Aged; My | 1967 |
[Effect of potassium and magnesium aspartate on experimental myocardial ischemia and infarction].
Topics: Animals; Aspartic Acid; Cats; Coronary Disease; Female; Magnesium; Male; Myocardial Infarction; Pota | 1984 |
[Electrocardiographic localization of myocardial infarct and the activity of various blood serum enzymes in the acute stage of the disease].
Topics: Acute Disease; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aspartic Acid; Clinic | 1980 |
Isoelectric focusing, and other physical, kinetic properties of GOT isoenzymes isolated from sera of myocardial infarction patients.
Topics: Acetates; Aspartate Aminotransferases; Aspartic Acid; Calcium; Female; Fumarates; Humans; Hydrogen-I | 1980 |
Intracoronary magnesium is not protective against acute reperfusion injury in the regional ischaemic-reperfused dog heart.
Topics: Animals; Aspartic Acid; Coronary Circulation; Coronary Vessels; Dogs; Female; Hemodynamics; Humans; | 1995 |
Aspartate improves recovery of the recently infarcted rat heart after cardioplegic arrest.
Topics: Animals; Aspartic Acid; Cardioplegic Solutions; Heart Arrest, Induced; Male; Myocardial Contraction; | 1998 |
A common Glu298-->Asp (894G-->T) mutation at exon 7 of the endothelial nitric oxide synthase gene and vascular complications in type 2 diabetes.
Topics: Albuminuria; Amino Acid Substitution; Angina Pectoris; Aspartic Acid; Cerebrovascular Disorders; Dia | 1998 |
Ehlers-Danlos syndrome type IV with a unique point mutation in COL3A1 and familial phenotype of myocardial infarction without organic coronary stenosis.
Topics: Adult; Aneurysm; Aspartic Acid; Collagen; Coronary Disease; Ehlers-Danlos Syndrome; Emphysema; Glyci | 2001 |
Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arteriosclerosis; Aspartic Acid; Brain Infarction; Cardi | 2001 |
[Potassium magnesium asparate in the treatment of myocardial infarct. Clinical experiences].
Topics: Aged; Arrhythmias, Cardiac; Aspartic Acid; Female; Humans; Male; Middle Aged; Myocardial Infarction; | 1979 |
[Change in the protein and electrolyte metabolism under the effect of anabolic steroids and panangin in patients with myocardial infarct].
Topics: Anabolic Agents; Aspartic Acid; Blood Proteins; Humans; Myocardial Infarction; Potassium; Potassium | 1978 |
Proceedings: Influence on the running performance of isoprenaline damaged rats.
Topics: Animals; Aspartic Acid; Isoproterenol; Magnesium; Male; Myocardial Infarction; Physical Exertion; Po | 1975 |
Morphological changes after simultaneous administration of isoproterenol (ISO) and K+,MG2+-Aspartate (KMg-ASP) as a physiological Ca2+ antagonist.
Topics: Animals; Aspartic Acid; Calcium; Dogs; Extracellular Space; Glycogen; Histocytochemistry; Isoprotere | 1975 |
[Influencing myocardial necroses induced by isoproterenol, the physiologic antagonist of calcium, in experiments (author's transl)].
Topics: Animals; Aspartic Acid; Calcium; Dogs; Isoproterenol; Male; Myocardial Infarction; Myocardium; Necro | 1975 |
[Drug prevention of cardiac rhythm disorders during the acute period of myocardial infarct].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspartic Acid; Drug Therapy, Combination; | 1976 |
Reduction of infarct size by systemic amino acid supplementation during reperfusion.
Topics: Animals; Aspartic Acid; Glutamates; Glutamic Acid; Hemodynamics; Myocardial Infarction; Myocardial R | 1991 |
Reduction of infarct size by systemic amino acid supplementation during reperfusion.
Topics: Animals; Aspartic Acid; Glutamates; Glutamic Acid; Hemodynamics; Myocardial Infarction; Myocardial R | 1991 |
Reduction of infarct size by systemic amino acid supplementation during reperfusion.
Topics: Animals; Aspartic Acid; Glutamates; Glutamic Acid; Hemodynamics; Myocardial Infarction; Myocardial R | 1991 |
Reduction of infarct size by systemic amino acid supplementation during reperfusion.
Topics: Animals; Aspartic Acid; Glutamates; Glutamic Acid; Hemodynamics; Myocardial Infarction; Myocardial R | 1991 |
[Protection and reperfusion of the myocardium by cardioplegia with blood enriched in aspartate and glutamate. Technique and initial results. Report of 60 cases].
Topics: Adult; Aged; Aspartic Acid; Blood Transfusion; Cardioplegic Solutions; Clinical Protocols; Extracorp | 1990 |
Studies on prolonged acute regional ischemia. V. Metabolic support of remote myocardium during left ventricular power failure.
Topics: Animals; Aspartic Acid; Coronary Circulation; Dogs; Glucose; Glutamates; Hemodynamics; Infusions, In | 1989 |
Effect of aspartate and glutamate on experimental myocardial infarction in rats.
Topics: Animals; Aspartic Acid; Female; Glutamates; Isoproterenol; Male; Myocardial Infarction; Rats | 1989 |
[Mechanisms of ammonia binding in the heart muscle].
Topics: Alanine; Amino Acids; Ammonia; Animals; Aspartic Acid; Glutamates; Glutamic Acid; Glutamine; In Vitr | 1985 |
An assessment of anaerobic metabolism during ischemia and reperfusion in isolated guinea pig heart.
Topics: Adenine Nucleotides; Anaerobiosis; Animals; Aspartic Acid; Citric Acid Cycle; Coronary Disease; Glut | 1988 |
[Arrhythmias in acute myocardial infarct].
Topics: Acidosis; Acute Disease; Arrhythmias, Cardiac; Aspartic Acid; Atrial Fibrillation; Atrial Flutter; B | 1973 |
[Physiopathology and pharmacology of myocardial necrosis].
Topics: Animals; Aspartic Acid; Dihydroxyphenylalanine; Glucose; Heart; Humans; Insulin; Lysosomes; Monoamin | 1974 |
Effect of potassium and magnesium aspartate on the serum free-fatty-acids levels in patients with acute myocardial infarction.
Topics: Adult; Aged; Aspartic Acid; Depression, Chemical; Fatty Acids, Nonesterified; Female; Humans; Magnes | 1974 |
[Treatment of acute myocardial infarct and chronic heart failure using potassium-magnesium aspartate].
Topics: Adult; Aged; Arrhythmias, Cardiac; Aspartic Acid; Digitalis Glycosides; Heart Failure; Humans; Magne | 1974 |
Computer simulation and optimization, as exemplified by the enzyme-coupled aminotransferase (transaminase) assays.
Topics: Alanine; Alanine Transaminase; Animals; Aspartate Aminotransferases; Aspartic Acid; Computers; Evalu | 1974 |
[Effect of L-aspartic acid on the carbohydrate-phosphorus metabolism of the heart muscle in the acute period of experimental myocardial infarct].
Topics: Acute Disease; Aerobiosis; Animals; Aspartic Acid; Carbohydrate Metabolism; Glycolysis; Heart; Isoen | 1972 |
Pharmacological control of cardiac metabolism during acute heart failure.
Topics: Animals; Aspartic Acid; Blood Pressure; Calcium; Cardiac Output; Dogs; Dose-Response Relationship, D | 1973 |
[Radioisotope indication of metabolic processes in the myocardium and liver during the acute period of experimental myocardial ischemia].
Topics: Acetates; Amino Acids; Animals; Aspartic Acid; Carbon Radioisotopes; Glucose; Liver; Myocardial Infa | 1974 |
On relationships between synthesis of DNA and incorporation of deoxythymidine into DNA during myocardial infarctions induced in rats by isoproterenol.
Topics: Adenine; Animals; Aspartic Acid; Carbon Dioxide; Carbon Isotopes; Cytosine; DNA; Female; Formates; G | 1972 |
[On the effect of potassium, magnesium aspartate therapy in various heart diseases].
Topics: Aged; Aspartic Acid; Electrocardiography; Female; Heart Diseases; Humans; Infusions, Parenteral; Mag | 1967 |
[Preliminary report on the use of so-called electrolyte binders in myocardial infarct].
Topics: Adult; Aged; Anticoagulants; Aspartic Acid; Cardiac Glycosides; Electrocardiography; Female; Humans; | 1967 |
[Experimental study on the effects of polarizing solutions with and without ATP on the electrocardiographic pattern of myocardial ischemia caused by pitressin].
Topics: Adenosine Triphosphate; Animals; Aspartic Acid; Electrocardiography; Glucose; Insulin; Male; Myocard | 1967 |
[Therapy of disorders of myocardial metabolism with potassium-magnesium aspartate].
Topics: Adult; Aged; Aspartic Acid; Coronary Disease; Electrocardiography; Female; Heart Diseases; Humans; M | 1967 |
[On infusion therapy with potassium-magnesium aspartate in acute myocardial infarct, chronically insufficient heart and digitalis intoxication].
Topics: Adult; Aged; Aspartic Acid; Digitalis Glycosides; Electrocardiography; Female; Heart Failure; Humans | 1968 |
[Levels of free amino acids in the blood and heart muscle in the human at various periods of myocardial infarct (clinical anatomical parallels)].
Topics: Alanine; Amino Acids; Arginine; Aspartic Acid; Chromatography; Erythrocytes; Glutamates; Glycine; Hi | 1968 |
[Treatment of coronary heart disease from the modern point of view].
Topics: Adult; Angina Pectoris; Animals; Aspartic Acid; Blood Circulation; Coronary Disease; Coronary Vessel | 1968 |
[The effects of potassium-magnesium aspartate on experimental bioelectric disturbances in cerebral activity induced by a "cardiopathogenic diet"].
Topics: Animals; Aspartic Acid; Brain Damage, Chronic; Diet; Electroencephalography; Magnesium; Myocardial I | 1965 |